Number 26, 2005
Cardiovascular effects of exercise
Cardiac adaptation to exercise
Back to the Summary
Harm Kuipers
Faculty of Health Sciences,
Maastricht University,
Maastricht,
The Netherlands
Correspondence: Dr Harm Kuipers,
Faculty of Health Sciences,
Maastricht University,
PO Box 616,
6200
MD Maastricht,
The Netherlands.
E-mail: harm.kuipers@bw.unimaas.nl
|
Abstract
Regular training elicits specific adaptations to heart structure and function, resulting in increased heart performance and increased exercise capacity. The autonomic control also adjusts to training, and at rest a high parasympathetic tone results in bradycardia with increased stroke volume. Some athletes use drugs to boost sport performance. Androgenic anabolic steroids may alter the serum lipid profile unfavorably. There is no conclusive evidence for cardiac structural and functional changes with the use of these drugs. Erythropoietin not only may enhance sport performance, but also can increase the risk of thromboembolism. Amphetamines can induce acute heart failure, hyperthermia, and sudden death during exercise. ? Heart Metab. 2005;26:3134.
Keywords: Autonomic nervous system, training, doping, heart
|
Introduction
Regular physical exercise induces changes in the body that are a physiological adaptation to increased loads. In general, these adaptations are favorable and enable the individual to increase physical performance capacity. Adaptations to training also include the structure and function of the cardiovascular system, in addition to its functional control (Figure 1 [1]). Strength training induces changes to pressure loads, whereas endurance training requires volume loads and elicits an increased maximal cardiac output, by increasing stroke volume [2]. Compared with the maximal cardiac output in non athletic adults of approximately 25L/min, that of elite athletes can reach values of up to 3035L/min [2].

Figure 1. M-Mode echocardiographic tracings obtained from an elite male rower, (a) at the peak of athletic conditioning and (b) after an 8-week period of deconditioning. The ventricular septum shows a reduction in thickness from 13mm (a) to 10mm (b). (From Pelliccia and Maron [1], with permission.)
It has become clear that sport performances and training-induced adaptations are determined mainly by genetic factors and to a limited extent by training [3]. Because of these limitations in training adaptations, athletes may be tempted to use performance-enhancing drugs to push their performance further.
Autonomic control with training
Adaptations to regular exercise also include the autonomic control of cardiovascular function [4,5]. Regular training causes adjustments in the autonomic nervous system that may change the physiological response of the heart and blood vessels to exercise, and increase its functional capacity (Figure 2). The speed of depolarization and conduction velocity of myocardial cells determine heart rhythm, which can be changed by different input from the autonomic fibers [4,7]. Increased sympathetic activity leads to increased heart rate and increased contractility, whereas increased parasympathetic input retards heart rate and decreases contractility [4,7]. Endurance-trained individuals are characterized by an increased parasympathetic tone at rest, which is reflected in bradycardia and compensatory increased stroke volume [8] (Figure 3). Because of an increased parasympathetic tone and slow pulse rate in the resting state in well-trained athletes, the baroreflex may not always adequately counteract the blood pressure changes associated with sudden changes in posture [10]. Because of this, endurance-trained athletes may be more susceptible than untrained individuals to orthostatic hypotension with sudden changes in posture [10]. A profession that is associated with sudden changes in static pressure from sudden changes in G-forces is that of fighter pilot. Although the author is not aware of relevant published data, it is possible that fighter pilots who are endurance trained and have a pronounced bradycardia may have a less adequate baroreflex and a lower G-force tolerance than non trained individuals. In that case, special attention should be given to teaching strategies for coping with high G-forces in flight [11].

Figure 2. Interaction between left ventricular dimensions and wall stress. (a) Normal left ventricle (untrained). (b) After chamber enlargement without left ventricular hypertrophy (ie, cardiomyopathy. (c) After endurance training (increased ventricular chamber volume and modest hypertrophy). LV, left ventricular. (From Goodman [6], with permission.)
Figure 3. The athlete's heart. As a simplification, the adaptations involved in dynamic exercise training may be regarded as compensatory responses to a chronic volume load, including physiological cardiomegaly. BP, blood pressure. (From Opie [9], with permission.)
Doping in sport and the heart
In sports in which muscle strength and muscle mass are determining factors for success, it has been shown that the use of androgenic anabolic steroids can enhance sport performance [12]. In spite of the positive effects on performance, the use of such drugs may have serious adverse effects that also involve the cardiovascular system. The abuse of androgenic anabolic steroids has been associated with an increased risk for serious cardiovascular events such as myocardial infarction, cerebrovascular accidents, acute heart failure, and thromboembolism [12]. It has been demonstrated that the use of androgenic anabolic steroids can unfavorably affect some risk factors for cardiovascular disease, especially the serum lipid profile. In athletes, administration of high doses of these drugs may lead to decreased concentrations of high-density lipoprotein cholesterol [13]. However, the effects of androgenic anabolic steroid abuse are reversible and, after administration is stopped, serum lipids return to pre-drug concentrations [13].
There is some indication from cross-sectional echocardiography and from animal studies that abuse of androgenic anabolic steroids may change cardiac structure and function. Some investigators reported larger ventricular mass and interventricular septal thickness in association with the use of the drugs. Others could not confirm these changes [12]. One prospective study reported echocardiographic changes during use of androgenic anabolic steroids [14], whereas other studies failed to show any significant change to ventricular parameters [12]. Thus, at present, it remains to be established whether the use of androgenic anabolic steroids by athletes does affect cardiac structure and function.
Another drug that is abused, especially in endurance sports, is erythropoietin. It has been shown that the administration of erythropoietin increases hemoglobin mass and oxygen transport capacity, and hence endurance performance [15]. However, with an increase in hemoglobin mass, blood viscosity increases, which may lead to hypertension and thromboembolic events [16]. It is rumored that some athletes use aspirin to prevent thromboembolism. Although never proven, it has been suggested that the sudden death of some young athletes in the late 1980s and early 1990s was associated with the use of erythropoietin. Some large international sport bodies have introduced regular blood testing in athletes in order to monitor their hematological profile and detect and prevent possible manipulation [14].
A drug that was frequently abused in the sport of cycling during the 1960s was amphetamine. In contrast to popular belief, amphetamine is not a strong performance enhancer in high-intensity events; nevertheless, its use is widespread [85]. However, amphetamines may be cardiotoxic and may cause acute infarction and sudden death [18]. In addition, heat dissipation during exercise is impaired, which may lead to hyperthermia and cardiac failure [18]. After some deaths occurred in athletes during competition, the International Olympic Committee put a ban on the use of these drugs. Although no evidence is available, it cannot be ruled out that regular use of amphetamines or other performance-enhancing drugs may cause structural, functional, and possibly irreversible changes to the heart. ?
Back to the Summary
REFERENCES
1. Pelliccia A, Maron BJ.
Outer limits of the athlete's heart, the effect of gender and relevance to the differential diagnosis with primary cardiac diseases. Cardiology Clinics. 1997:15:381396.
2. Astrand PO, Rodahl K, Dahl HA, Strψmme SB.
Body fluids, blood and circulation. Textbook of Work Physiology. Human Kinetics. 4th ed. Illinois, USA; 2003:127176.
3. Andersen JL, Scherling P, Saltin B.
Muscle, genes and athletic performance. Sci Am. 2000;283:4855. PMID: 10976466 [PubMed - indexed for MEDLINE]
4. Dickhuth HH, Rocker K, Mayer F, Konig D, Korsten-Reck U.
Cardiovascular adaptation to endurance training (athletes's heart). Herz. 2004;29:373380. PMID: 15241536 [PubMed - indexed for MEDLINE]
5. Kaciuba-Uscilko H, Smorawinski J, Nazar K, Adrian J, Greenleaf JE.
Catecholamine reponses to environmental stressors in trained and untrained men after 3-day bed rest. Aviat Space Environ Med. 2003;74:928936. PMID: 14503670 [PubMed - indexed for MEDLINE]
6. Goodman J,
The athletes heart. In: Shepard RJ, Astrand PO, eds. Endurance in Sport. Blackwell Science Ltd, London; 1992;6883.
7. Stein R, Moraes RS, Cavalcanti AV, Ferlin EL, Zimerman LI, Ribeiro JP.
Atrial automaticity and atrioventricular conduction in athletes: contribution of autonomic regulation. Eur J Appl Physiol. 2000;82:155717. PMID: 10879458 [PubMed - indexed for MEDLINE]
8. Carter JB, Bannister EW, Blaber AP.
Effect of endurance exercise on autonomic control of heart rate. Sports Med. 2003;33:3346. PMID: 12477376 [PubMed - indexed for MEDLINE]
9. Opie LH,
The Heart: Physiology, from cell to cirulation
Lippincott-Raven, Philadelphia, USA; 1998.
10. Morikawa T, Sagawa S, Torii R, Endo Y, Yamazaki F, Shiraki K.
Hypovolemic intolerance to lower body negative pressure in female runners. Med Sci Sports Exerc. 2001;33:20582064. PMID: 11740299 [PubMed - indexed for MEDLINE]
11. Convertino VA.
High sustained +Gz acceleration: physiological adaptation to high-G tolerance. J Grav Physiol. 1998;5:P51P54.
12. Hartgens F, Kuipers H.
Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:142. PMID: 15248788 [PubMed - indexed for MEDLINE]
13. Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BHR.
Effects of androgenic anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med. 2004;38:253259. PMID: 15155420 [PubMed - indexed for MEDLINE]
14. Sachtleben TR, Berg KE, Elias BA, Cheatham JP, Felix GL, Hofshire PJ.
The effects of anabolic streroids on myocardial structure and cardiovascular fitness. Med Sci Sports Exerc. 1993;25:12401245. PMID: 8289610 [PubMed - indexed for MEDLINE]
15. Ekblom B, Berglund B.
Effect of erythropoietin administration on maximal aerobic power. Scand J Med Sci Sports. 1991;1:8893.
16. Gaudard A, Varlet-Marie E, Bressole F, Audran M.
Drugs for increasing oxygen transport and their potential use in doping. Sports Medi. 2003;33:187212.
17. Gore CJ, Parisotto R, Ashenden MJ, et al.
Second generation blood tests to detect erythropoietin abuse in athletes. Haematologica. 2003;88:333344. PMID: 12651273 [PubMed - indexed for MEDLINE]
18. Karch SB.
Stimulants. In: Bahrke, Yesalis, eds. Performance Enhancing Substances in Sport and Exercise. Human Kinetics. Illinois, USA; 2002:257266.
Back to the Summary
|